Medicaid’s cost for ADHD drugs rose dramatically in the past decade, mostly driven by off-label use of antipsychotics for ADHD in youth.

Posted on March 19, 2013 in ADHD [Attention Deficit Hyperactivity Disorder], Adverse effects, Neuroleptic (antipsychotics), Over-medication of children with psychotropics, Psychiatric labels, Psychotropic Medications

More info:

The authors examined a large, state Medicaid database between 1996 and 2005to determine spending on medications for 107,486 children (3 to 17 years old) diagnosed with ADHD . Spending on stimulant medications increased 157% during this period due to increases in the price of prescriptions; during this time, there was a 588% increase in antipsychotic spending due to large increases in price and quantity used.

From the source:

“Because both neurological and metabolic side effects are more substantial in a pediatric population, expansion of the off-label use of antipsychotics among children with ADHD not only drives spending, but also raises concerns about possible overtreatment.”

Citation:

Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG. Medication use and spending trends among children with ADHD in Florida’s Medicaid program, 1996-2005. Psychiatr Serv. 2012;63(2):115-121.

***

Created by Lydia Green, RPh.
RxBalance. July 2012